Program
follitropin alfa
Also written as “Gonal-f”, “Follitropin alfa (Primapur)” and “Gonal-f®”.
Its studies are mostly in Infertility · Infertility, Female · Hypogonadism · Anovulation, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 131 open or running | phase 4since Nov 4, 2005 | Nov 4, 2005 | Sep 30, 2027phase 3 · NCT07340827 |
| IVFarma | 20 open or running | phase 3since Mar 2, 2017 | Mar 2, 2017 | none ahead |
| Bharat Serums and Vaccines | 11 open or running | phase 3since Jan 23, 2022 | Jan 23, 2022 | none ahead |
| Changchun GeneScience Pharmaceutical | 10 open or running | phase 3since Jan 5, 2015 | Jan 5, 2015 | none ahead |
| Fertility Biotech | 10 open or running | phase 1since May 19, 2015 | May 19, 2015 | none ahead |
| finox-ag | 10 open or running | phase 3since May 10, 2010 | May 10, 2010 | none ahead |
| Gema Biotech | 10 open or running | phase 3since May 22, 2015 | May 22, 2015 | none ahead |
| IBSA Institut Biochimique | 10 open or running | phase 3since Sep 15, 2006 | Sep 15, 2006 | none ahead |
| MinaPharm Pharmaceuticals | 10 open or running | phase 4since Nov 30, 2016 | Nov 30, 2016 | none ahead |
| Qilu Pharmaceutical | 11 open or running | phase 1since Mar 4, 2025 | Mar 4, 2025 | none ahead |
Also a collaborator on its studies: Merck Serono Middle East FZ, Merck Serono GmbH, Germany, Merck Serono Co., Ltd., Japan and Merck Serono S.P.A., Italy.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 9 studies since Nov 4, 2005.
- Dec 20, 2011Phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT01497197 · 174 enrolled · United Arab Emirates
- Jun 4, 2013Phase 4 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT01871532 · 24 enrolled · Ireland, United Kingdom
- Jan 5, 2015Changchun GeneScience Pharmaceutical's first study: phase 3 study in AnovulationNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT02335879 · 534 enrolled
- May 19, 2015Fertility Biotech's first study: phase 1 study in Healthy VolunteersNew to Fertility BiotechFertility Biotech · NCT02459418 · 42 enrolled · United Kingdom
- May 22, 2015Gema Biotech's first study: phase 3 study in InfertilityNew to Gema BiotechGema Biotech · NCT02454556 · 106 enrolled · Argentina
- Nov 30, 2016MinaPharm Pharmaceuticals's first study: phase 4 study in Infertility, FemaleNew to MinaPharm PharmaceuticalsMinaPharm Pharmaceuticals · NCT03057574 · 200 enrolled · Egypt
- Mar 2, 2017IVFarma's first study: phase 3 study in Infertility, FemaleNew to IVFarmaIVFarma · NCT03088137 · 118 enrolled · Russian Federation
- Feb 26, 2019Phase 1 study in Area Under CurveIVFarma · NCT03857230 · 28 enrolled · Russian Federation
- May 19, 2021Phase 1 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT04899193 · 72 enrolled · China
- Jan 23, 2022Bharat Serums and Vaccines's first study: phase 3 study in Infertility, FemaleNew to Bharat Serums and VaccinesBharat Serums and Vaccines · NCT05266924 · 250 enrolled · India
- Mar 4, 2025Qilu Pharmaceutical's first study: phase 1 study in Infertility, FemaleNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT06864793 · 48 enrolled · China
- Jul 15, 2025Phase 1 study in HypogonadismMerck KGaA, Darmstadt, Germany · NCT07097259 · 55 enrolled · United States
- Nov 17, 2025Phase 1 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07269327 · 24 enrolled · United Kingdom
- Jan 6, 2026Phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07340827 · 266 planned · Japan
Ahead
- Sep 30, 2027Primary completion: phase 3 study in InfertilityMerck KGaA, Darmstadt, Germany · NCT07340827
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Follicle Stimulating Hormonerule | glycotope-gmbh | phase 4 | 6 |
| follitropin deltarule | Ferring Pharmaceuticals | phase 3 | 18 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07340827Infertility · Japan | 3 | Recruiting | Merck KGaA, Darmstadt, Germany | Sep 30, 2027 | 266 |
| NCT07269327Infertility · United Kingdom | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 9, 2026 | 24 |
| NCT07097259Hypogonadism · United States | 1 | Completed | Merck KGaA, Darmstadt, Germany | Dec 23, 2025 | 55 |
| NCT06864793Infertility, Female · China | 1 | Active, not recruiting | Qilu Pharmaceutical | Feb 4, 2026 | 48 |
| NCT05266924Infertility, Female · India | 3 | Active, not recruiting | Bharat Serums and Vaccines | Aug 31, 2023 | 250 |
| NCT04899193Infertility · China | 1 | Completed | Merck KGaA, Darmstadt, Germany | May 28, 2022 | 72 |
| NCT03857230Area Under Curve · Russian Federation | 1 | Completed | IVFarma | May 10, 2016 | 28 |
| NCT03088137Infertility, Female · Russian Federation | 3 | Completed | IVFarma | Aug 17, 2018 | 118 |
| NCT03057574Infertility, Female · Egypt | 4 | UNKNOWN | MinaPharm Pharmaceuticals | Dec 2017 | 200 |
| NCT02454556Infertility · Argentina | 3 | Completed | Gema Biotech | Dec 2016 | 106 |
| NCT02459418Healthy Volunteers · United Kingdom | 1 | Completed | Fertility Biotech | May 19, 2016 | 42 |
| NCT02335879Anovulation | 3 | Completed | Changchun GeneScience Pharmaceutical | Aug 2009 | 534 |
| NCT01871532Infertility · Ireland, United Kingdom | 4 | Terminated | Merck KGaA, Darmstadt, Germany | Mar 2014 | 24 |
| NCT01497197Infertility · United Arab Emirates | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Jan 2014 | 174 |
| NCT01183143Infertility · Germany | 3 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2, 2006 | 215 |
| NCT01185782Infertility · Japan | 3 | Completed | Merck KGaA, Darmstadt, Germany | Dec 2007 | 300 |
| NCT01121666Infertility · Austria, Denmark, Germany and more | 3 | Completed | finox-ag | Dec 2011 | 460 |
| NCT01081626Infertility · Kuwait, Lebanon, Saudi Arabia | 4 | Completed | Merck KGaA, Darmstadt, Germany | Mar 2011 | 310 |
| NCT01081639Infertility | 3 | Completed | Merck KGaA, Darmstadt, Germany | Sep 2004 | 34 |
| NCT01071200Helping Behavior · Italy | 3 | Terminated | Merck KGaA, Darmstadt, Germany | Apr 2009 | 133 |
| NCT00829244Infertility · Switzerland | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jan 2010 | 200 |
| NCT00378001Infertility · United States | 3 | Completed | IBSA Institut Biochimique | May 2006 | 152 |
| NCT00249834Infertility · France | 4 | Completed | Merck KGaA, Darmstadt, Germany | Jan 16, 2006 | 166 |
How it is read
Names in the registry
- “Gonal-f”, 2 entries
- “Follitropin alfa (Primapur)”, 2 entries
- “Gonal-f®”, 2 entries
- “GONAL-f®”, 2 entries
- “GONAL f® prefilled pen”, 2 entries
Conditions, from the studies’ own filings
- Infertility, 15 studies
- Infertility, Female, 5 studies
- Hypogonadism, 1 study
- Anovulation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.